• Applied Use-Cases of Ertugliflozin (PF-04971729) in Diabetes

  2026-07-29

  Ertugliflozin (PF-04971729) is redefining experimental strategies in diabetes mellitus research, enabling precise modeling of glucose reabsorption inhibition and downstream cardiometabolic outcomes. This article delivers actionable workflows, troubleshooting insights, and comparative perspectives that empower scientists to unlock the full translational and technical potential of this selective SGLT2 inhibitor.

• Sildenafil Citrate: Advanced PDE5 Inhibitor Workflows in Vas

  2026-07-28

  Sildenafil Citrate from APExBIO empowers researchers to dissect cGMP-mediated signaling and proteoform-specific interactions with unprecedented selectivity and reproducibility. This guide demystifies experimental workflows, highlights novel insights from native proteomics, and provides actionable troubleshooting strategies for cardiovascular and cell signaling research.

• Suppressing Ephx2 Restores Erectile Function in Hypertensive

  2026-07-28

  This study identifies Ephx2 upregulation as a key contributor to endothelial dysfunction and erectile impairment in spontaneously hypertensive rats. By silencing Ephx2 in penile tissue, researchers demonstrated restoration of AKT/eNOS signaling and improved erectile parameters, highlighting a potential molecular target for hypertension-associated erectile dysfunction.

• Protease and Phosphatase Inhibitor Cocktail (EDTA Free, 100X

  2026-07-27

  The Protease and Phosphatase Inhibitor Cocktail (EDTA Free, 100X in ddH2O) addresses the critical need to prevent protein degradation and dephosphorylation during extraction from diverse biological samples, without interfering with metal-dependent enzymes. This reagent is ideal for workflows where EDTA is contraindicated, but is not suitable when metal ion chelation is a requirement for full protease inhibition.

• CHI3L1-IN-5 (Compound Z17): Applied Workflows in Neuroinflam

  2026-07-27

  CHI3L1-IN-5 (Compound Z17) is a structure-activity optimized inhibitor enabling precise dissection of CHI3L1-mediated neuroinflammation and restoration of astrocytic amyloid-beta clearance. This article unpacks experimental workflows, troubleshooting strategies, and advanced applications, translating the latest research and product insights into actionable protocols for Alzheimer's and CNS disease modeling.

• Resazurin Cell Viability Assay Kit: Sensitive Workflows & So

  2026-07-26

  The Resazurin Cell Viability Assay Kit empowers laboratories with fast, ultra-sensitive, and non-toxic cell proliferation and cytotoxicity analysis. Discover how to optimize high-throughput workflows and troubleshoot common challenges using this versatile APExBIO solution.

• miR-196a Drives Esophageal Adenocarcinoma via MYC/TERT/NFκB

  2026-07-25

  This study uncovers how microRNA-196a enhances the aggressiveness of esophageal adenocarcinoma by activating the MYC/TERT/NFκB axis. The findings reveal mechanistic links between miR-196a, c-Myc protein accumulation, and epithelial-to-mesenchymal transition, highlighting new intervention points for cancer research.

• Sodium Phosphate Dibasic: Strategic Buffering for Translatio

  2026-07-24

  Discover how sodium phosphate dibasic (Na2HPO4) underpins assay reliability in aquatic toxicology and molecular biology. This thought-leadership article offers mechanistic insights, protocol strategies, and actionable guidance for translational researchers, bridging the gap between rigorous buffer design and ecological risk assessment.

• Dual-Action Airway Stent Suppresses Tracheal Restenosis via

  2026-07-24

  Zhao et al. developed an electrospun airway stent integrating anti-inflammatory and anti-angiogenic agents, achieving significant suppression of tracheal in-stent restenosis (TISR) in a preclinical rabbit model. The stent's dual mechanism—targeting inflammation and excessive vascularization—demonstrated reduced fibrosis, infection, and fibroblast activation, highlighting a promising translational direction for airway intervention.

• Resazurin Cell Viability Assay Kit: Precision for Bone Resea

  2026-07-23

  Discover how the Resazurin Cell Viability Assay Kit enables ultra-sensitive, non-toxic cell proliferation analysis with unique advantages for bone biology and pharmacological research. This in-depth guide reveals advanced applications, validated protocols, and critical insights to optimize your workflow.

• HA-Lipid Nanoparticles Enable Transdermal PTEN mRNA Immunoth

  2026-07-23

  Kim et al. introduce a hyaluronate-conjugated lipid nanoparticle (HA-LNP) system for efficient, transdermal delivery of PTEN mRNA to melanoma. This approach restores tumor suppressor function, overcomes immune evasion, and offers a clinically relevant strategy for localized mRNA-based cancer immunotherapy.

• Enhanced Lysosomal Exocytosis Links to Cartilage Pathology i

  2026-07-22

  This study reveals that increased lysosomal exocytosis, rather than substrate accumulation alone, is a primary driver of cartilage pathology in a zebrafish model of mucopolysaccharidosis type IVA (MPS IVA). By connecting altered lysosome-plasma membrane fusion to disrupted growth factor signaling, the findings open new avenues for research into lysosomal storage disorders and skeletal disease mechanisms.

• Streptavidin-HyperFluor 647: Precision Biotin Detection in P

  2026-07-22

  Streptavidin-HyperFluor™ 647 stands out as a sensitive, low-background solution for detecting biotinylated molecules in fluorescence-based assays. Its robust performance in advanced proteomic workflows and compatibility with the latest proximity labeling innovations enable unmatched data quality and reproducibility.

• Protease Inhibitor Cocktails: Enabling Precision in LD Metab

  2026-07-21

  This thought-leadership article explores how mechanistically informed use of broad-spectrum protease inhibitor mixtures, such as APExBIO’s Protease Inhibitor Cocktail (100X H₂O, EDTA Plus), is transforming the experimental landscape in lipid droplet (LD) metabolism and DFCP1-ATGL regulatory studies. Bridging new mechanistic insights with translational workflows, we examine best practices, competitive advantages, and strategic considerations for researchers aiming to unlock high-fidelity, reproducible data in the context of metabolic stress and nutrient-responsive signaling.

• Carvedilol in β-Adrenergic Receptor Research: Applied Workfl

  2026-07-21

  Carvedilol, a robust β-adrenergic receptor antagonist, enables advanced cardiovascular and hematopoietic research by uniquely combining receptor blockade with antioxidant action. This article details stepwise protocols, troubleshooting strategies, and the latest assay insights, translating recent findings into practical laboratory decisions.

454 records 10/31 page Previous Next First page 上5页 678910 下5页 Last page